Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1-Reference-Cited by-同舟云学术

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1

Published:2023-04 Issue: Volume:33 Page:100762
ISSN:2666-6065
Container-title:The Lancet Regional Health - Western Pacific
language:en
Short-container-title:The Lancet Regional Health - Western Pacific

Author:

Zuo Fanglei,Sun Rui,Abolhassani Hassan,Du Likun,Wang Yating,Vlachiotis Stelios,Bertoglio Federico,Schubert Maren^ORCID,Rezaei Nima,Chavoshzadeh Zahra,Guerra Concetta^ORCID,Cavalli Andrea,Andréll Juni,Kumagai-Braesch Makiko^ORCID,Xue Yintong,Cao Yunlong,Hust Michael,Robbiani Davide F.,Xie Xiaoliang Sunney,Hammarström Lennart,Marcotte Harold^ORCID,Pan-Hammarström Qiang

Publisher

Elsevier BV

Subject

Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine

Reference9 articles.

1. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2;Qu;Cell Host Microbe,2023

2. Low neutralization of SARS-CoV-2 Omicron BA. 2.75. 2, BQ. 1.1, and XBB. 1 by parental mRNA vaccine or a BA. 5-bivalent booster;Kurhade;Nat Med,2022

3. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution;Cao;Nature,2022

4. Antibody response to Omicron BA.4–BA.5 bivalent booster;Wang;N Engl J Med,2023

5. Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster;Marcotte;Signal Transduct Target Ther,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06

2. Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86;The Lancet Infectious Diseases;2024-01

3. Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study;Heliyon;2024-01

4. Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines;Frontiers in Immunology;2023-11-27

5. Safety and immunogenicity of COReNAPCIN^®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial;2023-11-02